Type 1 Diabetes Trial, Recruiting (NCT00097292)

Type 1 Diabetes Trial, Recruiting NCT00097292 Sponsor: University of South Florida Condition: Type 1 Diabetes

Printed from Voxsanity (voxsanity.com.au) — NCT00097292 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Type 1 Diabetes

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People aged 2 to 45 years old who have a close family member (such as a child, parent, or sibling) with type 1 diabetes
People aged 2 to 20 years old who have an extended family member (such as a cousin, niece, nephew, aunt, uncle, grandparent, or half-sibling) with type 1 diabetes
People aged 2 to 45 years old who are not related to someone with type 1 diabetes but have been found to have one or more islet antibodies (proteins in the blood that can signal diabetes risk)

Who may not be able to join:

People who already have diabetes
People who are currently using, or have previously used, medications to control blood sugar or diabetes
People who are currently using medications that affect the immune system (note: creams or inhalers of this type may still be acceptable — confirm with trial site)
People who have a serious ongoing illness that is likely to shorten life expectancy, or that may require long-term immune-suppressing medications during the course of the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 20 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Kevan Herold, M.D., Yale University

Phone: 1-800-425-8361

Australian sites

Walter and Eliza Hall Institute, Parkville, Victoria
61-3-9342 7063

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT00097292

Sponsor: University of South Florida

Phase: Not Applicable

Status: Recruiting

Condition: Type 1 Diabetes

Trial contact: 1-800-425-8361

More information: https://clinicaltrials.gov/study/NCT00097292

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People aged 2 to 45 years old who have a close family member (such as a child, parent, or sibling) with type 1 diabetes
People aged 2 to 20 years old who have an extended family member (such as a cousin, niece, nephew, aunt, uncle, grandparent, or half-sibling) with type 1 diabetes
People aged 2 to 45 years old who are not related to someone with type 1 diabetes but have been found to have one or more islet antibodies (proteins in the blood that can signal diabetes risk)

Who may not be able to join:

People who already have diabetes
People who are currently using, or have previously used, medications to control blood sugar or diabetes
People who are currently using medications that affect the immune system (note: creams or inhalers of this type may still be acceptable — confirm with trial site)
People who have a serious ongoing illness that is likely to shorten life expectancy, or that may require long-term immune-suppressing medications during the course of the study

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 20 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University of South Florida

Registry

ClinicalTrials.gov

Start date

1 February 2004

Est. completion

31 July 2030

Where this trial is recruiting

🇦🇺 Australia 🇨🇦 Canada 🇫🇮 Finland 🇮🇹 Italy 🇬🇧 United Kingdom 🇺🇸 United States

1 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Development of type 1 diabetes

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov